You are here

Article info

Article menu

Download PDFPDF

XML
Review
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Authors

  • Satya Das Vanderbilt University Medical CenterDepartment of Medicine, Division of Hematology and Oncology 1301 Medical Center Drive 37232 Nashville USA PubMed articlesGoogle scholar articles
  • Douglas B. Johnson Vanderbilt University Medical CenterDepartment of Medicine, Division of Hematology and Oncology 1301 Medical Center Drive 37232 Nashville USA PubMed articlesGoogle scholar articles
  1. ↵a (615) 936-8422 Satya.das{at}vumc.org
View Full Text

Citation

Das S, Johnson DB
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer 2019;7:306. doi: 10.1186/s40425-019-0805-8

Publication history

  • Received July 9, 2019
  • Accepted November 5, 2019
  • First published November 15, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.